

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June 2014

PART -1		(Rs in Lacs)			
Sr. No.	Particulars	3 Months Ended			Year Ended March 2014 Audited
		June 2014 Unaudited	March 2014 Audited	June 2013 Unaudited	
1	Income from Operation				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	-5,287.93	4,047.76	5,024.12	18,650.54
	(b) Other Operating Income	2.84	15.42	0.29	41.15
	Total Income From Operation (Net)	5,290.77	4,063.18	5,024.40	18,691.69
2	Expenditure				
	a) Cost of Material Consumed	2,815.89	2,395.11	2,982.30	10,675.04
	b) Purchase of Stock In Trade				
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	194.50	451.43	(449.98)	(120.67)
	d) Employee Benefit Expenses	463.57	561.92	400.83	1,852.29
	e) Depreciation and Amortisation Expenses	442.12	454.88	439.71	1,769.64
	f) Other Expenditure	1,619.53	2,897.11	1,771.93	7,953.57
	Total Expenses	5,535.61	6,760.45	5,144.79	22,129.87
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(244.85)	(2,697.27)	(120.39)	(3,438.18)
4	Other Income				
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(244.85)	(2,697.27)	(120.39)	(3,438.18)
6	Finance costs	1,421.03	1,398.03	1,292.35	5,424.19
7	Profit after Interest but before Exceptional items (5-6)	(1,665.88)	(4,095.30)	(1,412.74)	(8,862.37)
8	Exceptional items		3,359.78		3,359.78
9	Profit / (Loss) from ordinary activities before tax	(1,665.88)	(735.52)	(1,412.74)	(5,502.59)
10	Tax Expenses	91.89	192.54	85.00	367.54
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,757.77)	(928.06)	(1,497.74)	(5,870.13)
12	Extraordinary items (net of tax expense) Lakhs)				
13	Net Profit / (Loss) for the period (11 + 12)	(1,757.77)	(928.06)	(1,497.74)	(5,870.13)
14	Share of profit / (loss) of associates*				
15	Minority interest *				
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,757.77)	(928.06)	(1,497.74)	(5,870.13)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2,981.63	2,981.63	2,586.68	2,981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				11,827.41
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(5.90)	(3.11)	(5.79)	(19.69)
	(b) Diluted	(5.90)	(3.11)	(5.79)	(19.69)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(5.90)	(3.11)	(5.79)	(19.69)
	(b) Diluted	(5.90)	(3.11)	(5.79)	(19.69)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

PART -II


A		PARTICULARS OF SHAREHOLDING			
1	Public Shareholding				
	-No. of Shares	79,67,057	79,67,057	79,44,924	79,67,057
	-Percentage of shareholding	26.72%	26.72%	30.71%	26.72%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged/Encumbered				
	-No. of shares	1,50,76,441	1,50,76,441	1,79,21,907	1,50,76,441
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	69.00%	69.00%	100.00%	69.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	50.56%	50.56%	69.29%	50.56%
	b) Non-encumbered				
	-No. of shares	67,72,802	67,72,802		67,72,802
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	31.00%	31.00%		31.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	22.72%	22.72%		22.72%
	B		3 months ended (30.06.2014)		
Detail of Investor Compliant					
Pending at the beginning of the quarter		0			
Received during the quarter		3			
Disposed of during the quarter		3			
Remaining unresolved at the end of the quarter		0			

NOTES :

- 1 The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 14th August 2014.
- 2 The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- 3 The previous year/period have been regrouped/rearranged wherever found necessary.
- 4 The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

For and on behalf of Board of Directors

Place: Indore
Date: 14th August 2014


Anil Mittal
Whole Time Director

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June 2014

PART -1		3 Months Ended			(Rs in Lacs)
Sr. No.	Particulars	June 2014 Unaudited	March 2014 Audited	June 2013 Unaudited	Year Ended March 2014 Audited
1	Income from Operation				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	7,711.28	5,872.42	8,070.79	27,369.76
	(b) Other Operating Income	4.50	48.33	0.83	406.49
	Total Income From Operation (Net)	7,715.77	5,920.75	8,071.62	27,776.25
2	Expenditure				
	a) Cost of Material Consumed	4,345.80	4,265.48	4,850.39	16,397.66
	b) Purchase of Stock In Trade				
	c) Change in Inventories of Finished Goods, Work in Progress and Stock in trade	73.57	433.95	(372.68)	79.88
	d) Employee Benefit Expenses	596.51	743.31	472.09	2,192.78
	e) Depreciation and Amortisation Expenses	574.90	494.58	456.05	1,862.39
	f) Other Expenditure	2,429.18	3,971.74	2,623.15	11,342.72
	Total Expenses	8,019.96	9,909.06	8,029.00	31,875.43
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(304.18)	(3,988.31)	42.62	(4,099.18)
4	Other Income	-	-	-	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(304.18)	(3,988.31)	42.62	(4,099.18)
6	Finance costs	1,652.38	1,497.69	1,418.31	6,020.61
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional items (5-6)	(1,956.56)	(5,486.00)	(1,375.68)	(10,119.79)
8	Exceptional items		236.48	5,227.10	5,463.58
	Profit / (Loss) from ordinary activities before tax(7 + 8)	(1,956.56)	(5,249.52)	3,851.42	(4,656.21)
10	Tax Expenses	91.89	996.62	(1,228.62)	(139.18)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(2,048.45)	(6,246.14)	5,080.04	(4,517.03)
12	Extraordinary items (net of tax expense Lakhs)				
13	Net Profit / (Loss) for the period (11 + 12)	(2,048.45)	(6,246.14)	5,080.04	(4,517.03)
14	Share of profit / (loss) of associates*				
15	Minority interest *				
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(2,048.45)	(6,246.14)	5,080.04	(4,517.03)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2,981.63	2,981.63	2,586.68	2,981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				15,593.06
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(6.87)	(20.95)	19.64	(15.15)
	(b) Diluted	(6.87)	(20.95)	19.64	(15.15)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(6.87)	(20.95)	19.64	(15.15)
	(b) Diluted	(6.87)	(20.95)	19.64	(15.15)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

PART -II

A		PARTICULARS OF SHAREHOLDING			
1	Public Shareholding				
	-Number of Shares	79,67,057	79,67,057	79,44,924	79,67,057
	-Percentage of shareholding	26.72%	26.72%	30.71%	26.72%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged/Encumbered				
	-Number of shares	1,50,76,441	1,50,76,441	1,79,21,907	1,50,76,441
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	69.00%	69.00%	100.00%	69.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	50.56%	50.56%	69.29%	50.56%
	b) Non-encumbered				
	-Number of shares	67,72,802	67,72,802		67,72,802
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	31.00%	31.00%		31.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	22.72%	22.72%		22.72%
B	Detail of Investor Compliant	3 months ended (30.06.2014)			
	Pending at the beginning of the quarter	0			
	Received during the quarter	3			
	Disposed of during the quarter	3			
	Remaining unresolved at the end of the quarter	0			


NOTES :

- 1 The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 14th August 2014.
- 2 The unaudited financial results of the subsidiary companies have been consolidated.
- 3 The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- 4 The previous year/period have been regrouped/rearranged wherever found necessary.
- 5 The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

Sr. No.	Particulars	3 Months Ended			Year Ended March 2014 Audited
		June 2014 Unaudited	March 2014 Audited	June 2013 Unaudited	
1	Income from operations & other income	5,290.77	4,063.18	5,024.40	18,691.69
2	Profit/Loss before tax	(1,665.88)	(735.52)	(1,412.74)	(5,502.59)
3	Profit/Loss after tax	(1,757.77)	(928.06)	(1,497.74)	(5,870.13)

For and on behalf of Board of Directors

Place: Indore
Date: 14th August 2014


Anil Mittal
Whole Time Director